Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Enanta Pharmaceuticals Inc Market Cap
From what 4 stock analysts predict, the share price for Enanta Pharmaceuticals Inc (ENTA) might increase by 72.27% in the next year. This is based on a 12-month average estimation for ENTA. Price targets go from $12 to $30. The majority of stock analysts believe ENTA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Enanta Pharmaceuticals Inc has a total of 4 Wall St Analyst ratings. There are 3 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Enanta Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ENTA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ed Arce HC Wainwright & Co. | Buy | $27 | Reiterates | Aug 6, 2024 |
| Eric Joseph JP Morgan | Underweight | $10 | Maintains | Aug 6, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $22 | Maintains | May 7, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $27 | Maintains | May 7, 2024 |
| Eric Joseph JP Morgan | Underweight | $11 | Maintains | Feb 8, 2024 |
| Jay Olson Oppenheimer | Perform | $21 | Maintains | Nov 22, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $28 | Maintains | Nov 21, 2023 |
| Roy Buchanan JMP Securities | Outperform | $23 | Maintains | Nov 21, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $30 | Maintains | Oct 23, 2023 |
| Brian Abrahams RBC Capital | Sector Perform | $15 | Maintains | Oct 2, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $48 | Reiterates | Sep 19, 2023 |
| Jay Olson Oppenheimer | Perform | $25 | Maintains | Aug 9, 2023 |
| Roy Buchanan JMP Securities | Market Outperform | $42 | Maintains | Aug 8, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $48 | Reiterates | Aug 8, 2023 |
| Akash Tewari Jefferies | Hold | $18 | Downgrade | Aug 8, 2023 |
| Brian Abrahams RBC Capital | Sector Perform | $25 | Reiterates | Aug 8, 2023 |
| Jay Olson Oppenheimer | Perform | $30 | Reiterates | May 11, 2023 |
| Roy Buchanan JMP Securities | Outperform | $65 | Maintains | May 9, 2023 |
| Brian Abrahams RBC Capital | Sector Perform | $33 | Maintains | May 9, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $48 | Maintains | May 9, 2023 |
When did it IPO
2013
Staff Count
145
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jay R. Luly Ph.D.
Market Cap
$276.7M
In 2023, ENTA generated $79.2M in revenue, which was a decrease of -8.07% from the previous year. This can be seen as a signal that ENTA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 13 Oct 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company's RSV pipeline. The event will feature presentations and discussions with: Jamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Inst.
Sun, 17 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos.
Thu, 07 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at the Boston Convention and Exhibition Center in Boston, MA. Date: Thursday, October 12, 2.
Thu, 31 Aug 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that members of management will participate in four investor conferences being webcast in September and provide a business update: Wells Fargo Securities Healthcare Conference: Fireside Chat at 2:15 p.m. ET on September 7, 2023 H.C. Wainwright 25th Annual Global Investment Conference: Presentation.
Tue, 08 Aug 2023
Sentiment - NEGATIVE
Source - The Motley Fool
Summary - The clinical-stage biotech receives most of its revenue from a royalty agreement with AbbVie. Enanta has a pipeline with eight programs.
Mon, 07 Aug 2023
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Tara Kieffer - Senior Vice President of New Product Strategy and Development Conference Call Participants Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Ed Arce - H.C. Wainwright Eric Joseph - JP Morgan Roy Buchanan - JMP Securities Luke Herrmann - Baird Operator Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter Financial Results Conference Call.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
